Success Metrics

Clinical Success Rate
58.8%

Based on 10 completed trials

Completion Rate
59%(10/17)
Active Trials
0(0%)
Results Posted
60%(6 trials)
Terminated
7(30%)

Phase Distribution

Ph not_applicable
7
30%
Ph phase_2
4
17%
Ph phase_3
4
17%
Ph phase_4
5
22%

Phase Distribution

0

Early Stage

4

Mid Stage

9

Late Stage

Phase Distribution20 total trials
Phase 2Efficacy & side effects
4(20.0%)
Phase 3Large-scale testing
4(20.0%)
Phase 4Post-market surveillance
5(25.0%)
N/ANon-phased studies
7(35.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

52.6%

10 of 19 finished

Non-Completion Rate

47.4%

9 ended early

Currently Active

0

trials recruiting

Total Trials

23

all time

Status Distribution
Active(1)
Completed(10)
Terminated(9)
Other(3)

Detailed Status

Completed10
Terminated7
unknown3
Withdrawn2
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
23
Active
0
Success Rate
58.8%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (20.0%)
Phase 34 (20.0%)
Phase 45 (25.0%)
N/A7 (35.0%)

Trials by Status

unknown313%
enrolling_by_invitation14%
terminated730%
completed1043%
withdrawn29%

Recent Activity

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT05399693

Platelet Transfusion Refractoriness

Completed
NCT05796557Phase 4

ECMO Hemostatic Transfusions in Children

Completed
NCT05293106Phase 4

Assessing the Hemostatic Efficacy of Pathogen Reduced Platelets in Children Undergoing Cardiopulmonary Bypass Surgery: A Pilot Clinical Trial

Terminated
NCT06535360Phase 4

Efficacy of Pathogen Inactivation Strategies for Platelet Transfusion

Completed
NCT05038722

Function of Platelets Used for Transfusions

Enrolling By Invitation
NCT03045068Phase 4

Platelet Transfusion During Neonatal Open Heart Surgery

Completed
NCT04915287Phase 4

Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure

Unknown
NCT02074436Phase 2

PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)

Terminated
NCT03090919Not Applicable

The INFUSE Trial - Intervening With Platelet Transfusions in Sepsis

Withdrawn
NCT04807621Phase 2

Platelets or Fibrinogen as First-line Treatment for Bleeding During Pedatric Heart Surgery

Unknown
NCT04564651Not Applicable

Platelet Transfusion in Acute-on Chronic Liver Failure

Unknown
NCT03968484Not Applicable

Platelet Transfusion in Sepsis Trial

Withdrawn
NCT03195010Phase 2

Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia

Terminated
NCT03561909Not Applicable

Kinetics of Blood Platelets Transfused to Healthy Subjects

Completed
NCT02601131

Post-transfusion Platelet Count

Completed
NCT00000589Phase 3

Trial to Reduce Alloimmunization to Platelets (TRAP)

Completed
NCT01615146Not Applicable

Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot

Terminated
NCT01030211Not Applicable

Adult Dengue Platelet Study

Completed
NCT01642563Phase 3

Italian Platelet Technology Assessment Study

Terminated
NCT00577096Not Applicable

Effects of Exercise in Combination With Epoetin Alfa

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
23